Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, in some cases, […]
Stents
Reflow Medical has positive data for coronary drug-eluting stent
Reflow Medical today announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable stent system. San Clemente, California-based Reflow designed its stent system to transfer a proprietary drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The device’s retrievable scaffold therapy creates channels to increase the […]
MicroPort wins FDA breakthrough nod for drug-eluting stent
MicroPort announced that it received FDA breakthrough device designation for its Apollo Dream sirolimus target-eluting stent system. Apollo Dream, an investigational, balloon-expandable, rapid-exchange drug-eluting stent system, is designed to provide vascular scaffolding and restore. cerebral blood flow. It aims to treat intracranial atherosclerotic disease (ICAD), a leading cause of ischemic stroke. The stent incorporates a […]
Abbott earns CMS reimbursement win for Esprit drug-eluting scaffold
An Abbott (NYSE:ABT) official has shared a significant reimbursement win for its Esprit BTK drug-eluting scaffold system. On LinkedIn, SVP and President of Abbott Vascular, Julie Tyler, posted that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment status for Esprit BTK. TPT, a three-year program, ensures that Medicare beneficiaries can […]
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]
Teleflex enrolls first patient in dual-drug-eluting device study of coronary interventions for diabetes
Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial. The randomized, investigator-initiated trial evaluates a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. DUBSTENT DIABETES investigates the safety and efficacy of combining drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) implantation compared to single-device strategies […]
Abbott wins CE mark for Esprit drug-eluting, dissolving scaffold
Abbott (NYSE: ABT) announced today that it received CE mark for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit BTK offers treatment for people with peripheral artery disease (PAD) below the knee (BTK). Abbott designed it to keep arteries open and deliver the drug everolimus to support vessel healing. Following the therapy, the stent completely […]
Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]
Data backs Boston Scientific drug-eluting stent
Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]
R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study
R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]
